NCT00414921.

Study name	Public title: Preschool supplement to clonidine in ADHD (Kiddie‐CAT) Scientific title: as above
Methods	Randomised controlled parallel‐group trial Study duration: 16 weeks
Participants	Sample size (actual): 30 Inclusion criteria: Child with ADHD Child aged 4‐6 years Child attending a structured preschool or daycare Exclusion criteria Presence of a tic disorder of any kind or a known active heart disease for which it would be unsafe to use the study drugs Presence of pervasive developmental disorder, autism, mental disability, or serious psychiatric illness; Child not attending a structured preschool or daycare
Interventions	Clonidine MPH Clonidine plus PH Placebo
Outcomes	ADHD symptoms ASQ‐T. Assessed at baseline and at 16 weeks ASQ‐P. Assessed at baseline and at 16 weeks Quality of life CGAS. Assessed at baseline and at 16 weeks Non‐serious AEs AEs logs. Assessed at baseline and at 16 weeks Pittsburgh Side Effects Rating Scale. Assessed at baseline and at 16 weeks Vital signs. Assessed at baseline and at 16 weeks ECGs. Assessed at baseline and at 16 weeks
Starting date	September 2003
Contact information	Only names of primary investigators available: Floyd Randy Sallee, MD/PhD; Oscar Bukstein, MD; Donna Palumbo, PhD; William Pelham, PhD
Notes	Sponsor: University of Cincinnati and National Institute of Neurological Disorders and Stroke (NINDS) Declaration of interests: not reported